AI Issuer Brief
Arphra AILoading cached brief…
Price change · trailing returns
Live · FMP| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.35% | +12.56% | +8.23% | +1.24% | +1.44% | -9.41% | +33.82% | -6.55% | -45.72% | +110.30% | +721.41% |
Aftermarket
Live · FMPLast trade
$181.35
154 sh
Bid
$171.10
10 sh
Ask
$190.48
5 sh
Spread
$19.380
Fair value
Football field →Weighted blend
$111.03
-38.56% vs spot
Recommendation
Sell
12 of 13 methods
Method spread
3bull9bear
±5% threshold
Analyst PT consensus: $205.43 (+13.68%)
Total assets
$7.14B
Total debt
$3.07B
Cash & equiv
$213.77M
Operating CF
$737.65M
Free cash flow
$518.49M
Buybacks
-$360.67M
Analyst view
DB · price_targets + analyst_gradesConsensus target
$205.43
+13.68% upside
Low
$175.00
Median
$200.00
High
$260.00
Recent actions
0 ↑0 ↓8 hold
- Apr 01, 2026
- Mar 01, 2026
- Feb 01, 2026
- Jan 01, 2026
- Dec 01, 2025
News
DB · news_items- Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutionsbusinesswire.com·May 13, 2026
- Charles River Laboratories International Inc (CRL) Stock Down 5.2% -- Now Undervalued? GF Score: 79/100gurufocus.com·May 12, 2026
- Charles River Accelerates Digital Pathology with AI-Powered End-to-End Workflowbusinesswire.com·May 11, 2026
- Charles River Laboratories Announces First-Quarter 2026 Resultsbusinesswire.com·May 07, 2026
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 Dec 2025 | $994.23M | -$276.56M | $-5.62 |
| Q3 Sep 2025 | $1B | $54.42M | $1.10 |
| Q2 Jun 2025 | $1.03B | $52.33M | $1.06 |
| Q1 Mar 2025 | $984.17M | $25.47M | $0.50 |
| Q4 Dec 2024 | $1B | -$215.7M | $-4.22 |
| Q3 Sep 2024 | $1.01B | $68.68M | $1.33 |
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
LaPlume Joseph W officer: EVP, Corp Strategy & Develop | Buy | 25 | $4.36K | Mar 03, 2026 |
LaPlume Joseph W officer: EVP, Corp Strategy & Develop | Sell | 400 | $65.49K | Aug 22, 2025 |
LaPlume Joseph W officer: EVP, Corp Strategy & Develop | Sell | 800 | $126.08K | Aug 18, 2025 |
LaPlume Joseph W officer: EVP, Corp Strategy & Develop | Sell | 400 | $60.02K | Aug 07, 2025 |
MASSARO GEORGE director | Sell | 81 | $11.15K | May 15, 2025 |
MASSARO GEORGE director | Sell | 35 | $4.77K | May 15, 2025 |
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $4.02B | $507.84M | -$144.34M | $-2.91 | -3.59% |
| FY 2024 | $4.05B | $227.35M | $10.3M | $0.20 | +0.25% |
| FY 2023 | $4.13B | $617.26M | $474.62M | $9.22 | +11.49% |
| FY 2022 | $3.98B | $650.98M | $486.23M | $9.48 | +12.23% |
| FY 2021 | $3.54B | $589.86M | $390.98M | $7.60 | +11.04% |